Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Ryan SunDivision of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL.
Anand SrivastavaDivision of Nephrology, Department of Medicine, University of Illinois Chicago, Chicago, IL.
Joseph L ZapaterDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-1116-7776
Franklin NjokuDivision of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0003-4171-3202
Jin HanDivision of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL.
Zalaya IvyDivision of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-3185-1786
Marwah FarooquiDivision of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL.
Insia RizviDivision of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL.
Brian LaydenDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois Chicago, Chicago, IL.
Robert E MolokieDivision of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL.
Victor R GordeukDivision of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0003-4725-7295
Santosh L SarafDivision of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-8584-4194
Funding
Pathways of Cell-Free Hemoglobin in Sickle Cell NephropathyR01HL153161 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2020 to 2024
$2.0M
Functional MRI to Identify High-risk CKD PhenotypesR01DK139321 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Anand Srivastava · 2025 to 2026
$1.5M
Non-Invasive Imaging Biomarkers to Identify a High-Risk Chronic Kidney Disease PhenotypeK23DK120811 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SRIVASTAVA, ANAND · 2020 to 2024
$1.0M
Mentoring & Patient-Oriented Research in Sickle Cell-Related Kidney DiseaseK24HL177273 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Santosh Saraf · 2025 to 2026
abstractWe observed diabetes mellitus (DM) in 9.3% of adults with sickle cell disease (SCD), and DM predicted a sevenfold greater risk of chronic kidney disease progression adjusting for high-risk APOL1. Our results emphasize the clinical significance of DM in SCD.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Diabetes mellitus and APOL1 genotype increase the risk for chronic kidney disease progression in sickle cell disease. · full record | OpenQuestion